Novo says it’s submitted obesity pill for FDA approval

Pharmalittle: We're reading about a Novo challenge to Medicare talks, a scuttled FDA office, and more

Good morning, everyone, and welcome to another working week. We hope the weekend respite was relaxing and invigorating, because that oh-so familiar routine of deadlines, online meetings, and phone calls has predictably returned. But what can you do? The world, such as it is, continues to spin. So time to give it a nudge in a better direction by brewing cups of stimulation. Our choice today is coconut rum, a welcome shot for the needy neurons. Me…

Novo says it’s submitted obesity pill for FDA approval

A spokesperson confirmed the Danish drugmaker has asked U.S. regulators to clear an oral version of its weight loss drug Wegovy two years after reporting initial Phase 3 results.

Human Experiments on GLP-1 Pill Looking Extremely Promising

Forget injections. A new drug promises to be just as effective as Ozempic  — but is taken as a daily pill. Called orforglipron, the results of a new clinical trial announced Thursday by manufacturer Eli Lilly suggest that the pill could be a breakthrough in a class of drugs called GLP-1 agonists, which have become popular for their dual effectiveness in helping with weight loss and treating diabetes.  Though they have taken the world by storm, G…

Promising clinical trials on the GLP-1 pill Forget injections. A new drug promises to be as effective as Ozempic, but takes the form of a tablet... The post Promising clinical trials on the GLP-1 pill appeared first on World News.

StockWatch: Investors Hungry for Lilly after Diabetes Pill Aces Phase III Trial

No sooner did Eli Lilly (NYSE: LLY)’s oral diabetes candidate orforglipron make history Thursday as the first oral small molecule glucagon-like peptide-1 (GLP-1) receptor agonist to ace a Phase III trial when investors roared their approval with a buying surge that sent the pharma giant’s stock soaring Thursday. Lilly trumpeted positive topline results from ACHIEVE-1 (NCT05971940), showing that orforglipron met the trial’s primary endpoint of su…